WO2002101076A3 - Methods for targeted expression of therapeutic nucleic acid - Google Patents

Methods for targeted expression of therapeutic nucleic acid Download PDF

Info

Publication number
WO2002101076A3
WO2002101076A3 PCT/US2002/018650 US0218650W WO02101076A3 WO 2002101076 A3 WO2002101076 A3 WO 2002101076A3 US 0218650 W US0218650 W US 0218650W WO 02101076 A3 WO02101076 A3 WO 02101076A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
methods
therapeutic nucleic
expression vectors
targeted expression
Prior art date
Application number
PCT/US2002/018650
Other languages
French (fr)
Other versions
WO2002101076A2 (en
Inventor
Richard R Drake
Saurabh K Gupta
Kelly E Mercer
Robyn Mcmasters
Mary Pat Moyer
Original Assignee
Eastern Virginia Med School
Univ Arkansas
Incell Corp Llc
Richard R Drake
Saurabh K Gupta
Kelly E Mercer
Robyn Mcmasters
Mary Pat Moyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School, Univ Arkansas, Incell Corp Llc, Richard R Drake, Saurabh K Gupta, Kelly E Mercer, Robyn Mcmasters, Mary Pat Moyer filed Critical Eastern Virginia Med School
Priority to CA002460095A priority Critical patent/CA2460095A1/en
Priority to EP02744307A priority patent/EP1461427A4/en
Priority to AU2002345658A priority patent/AU2002345658A1/en
Priority to JP2003503826A priority patent/JP2005504520A/en
Publication of WO2002101076A2 publication Critical patent/WO2002101076A2/en
Publication of WO2002101076A3 publication Critical patent/WO2002101076A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

Expression vectors that include a pre-selected therapeutic nucleic acid operably linked to a tumor specific or cell type-speci fic promoter and a Tcf-4β-catenin enhancer are provided. The therapeutic nucleic acid preferably includes a gene encoding a therapeutic protein for treatment of, for example, cancer. Methods for targeted expression of therapeutic nucleic acid, and methods for treating cancer, utilizing the expression vectors described herein, are also provided. Host cells are also provided that have been transformed with the expression vectors described herein.
PCT/US2002/018650 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid WO2002101076A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002460095A CA2460095A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid
EP02744307A EP1461427A4 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid
AU2002345658A AU2002345658A1 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid
JP2003503826A JP2005504520A (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29783101P 2001-06-13 2001-06-13
US60/297,831 2001-06-13
US36113702P 2002-03-01 2002-03-01
US60/361,137 2002-03-01

Publications (2)

Publication Number Publication Date
WO2002101076A2 WO2002101076A2 (en) 2002-12-19
WO2002101076A3 true WO2002101076A3 (en) 2004-07-22

Family

ID=26970335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018650 WO2002101076A2 (en) 2001-06-13 2002-06-13 Methods for targeted expression of therapeutic nucleic acid

Country Status (5)

Country Link
EP (1) EP1461427A4 (en)
JP (1) JP2005504520A (en)
AU (1) AU2002345658A1 (en)
CA (1) CA2460095A1 (en)
WO (1) WO2002101076A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5976986B2 (en) * 2005-10-01 2016-08-24 チャールズ スタウト， Regulatable fusion promoter
KR20160002848A (en) * 2013-03-24 2016-01-08 오이신 바이오테크놀로지스 Systems and methods for the targeted production of a therapeutic protein within a target cell
CA3025301A1 (en) * 2016-05-25 2017-11-30 The Board Of Trustees Of The Leland Stanford Junior University Activity-dependent expression constructs and methods of using the same
CA3047140A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells
JP2021526505A (en) 2018-04-18 2021-10-07 オイシン バイオテクノロジーズ，インク． Methods for Producing Fused Lipid Nanoparticles and Fused Lipid Nanoparticles for Target Cell-Specific Production of Therapeutic Proteins and for the Treatment of Target Cell-Related Diseases, Diseases, or Disorders And how to use
CN110964747A (en) * 2019-11-26 2020-04-07 深圳市人民医院 Suicide gene adenovirus with high-efficiency specific expression in glioma cell and construction method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
AU783128B2 (en) * 2000-03-02 2005-09-29 Innovata Plc TCF responsive element

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
US6140052A (en) * 1997-03-20 2000-10-31 The Johns Hopkins University cMYC is regulated by Tcf-4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1461427A4 *

Also Published As

Publication number Publication date
EP1461427A4 (en) 2006-02-15
AU2002345658A1 (en) 2002-12-23
JP2005504520A (en) 2005-02-17
EP1461427A2 (en) 2004-09-29
CA2460095A1 (en) 2003-12-19
WO2002101076A2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
WO2001072957A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
WO2006050211A3 (en) Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2005047458A3 (en) Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2002010382A3 (en) Trp8, trp9 and trp10, markers for cancer
AU1254795A (en) Tumor necrosis factor-gamma
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO2005000087A3 (en) Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
MXPA03001930A (en) Tnf receptor-like molecules and uses thereof.
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2000053776A3 (en) Human kallikrein-like genes
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
WO2003085087A8 (en) Modified cea nucleic acid and expression vectors
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
WO2004013313A3 (en) Antisense nucleic acids
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO1995027070A1 (en) Dna expression vectors for use in the treatment of vascular diseases by gene therapy
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment
WO2000062815A3 (en) Novel pharmaceutical composition suitable for gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2460095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003503826

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002744307

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002744307

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002744307

Country of ref document: EP